Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520889 | 0.90 | MAPT (0.46) | ALDH1A1MAPTHTTKMT2APOLB | |
| SCHEMBL4503200 | 0.89 | PPARD (0.51) | HTR1ATACR3TACR1 | |
| SCHEMBL4523286 | 0.89 | CACNA1G (0.42) | ALDH1A1MAPTHTTKMT2APOLB | |
| SCHEMBL4498481 | 0.89 | POLB (0.44) | MAPTHTTKMT2APOLBSMN1; SMN2 | |
| SCHEMBL4515600 | 0.88 | CETP (0.46) | MAPTKMT2A | |
| SCHEMBL4524332 | 0.88 | PPARD (0.42) | HTR1ATACR3TACR1ALDH1A1MAPT | |
| SCHEMBL4523435 | 0.87 | STAT3 (0.46) | KMT2A | |
| SCHEMBL4501707 | 0.87 | CETP (0.44) | ALDH1A1MAPT | |
| SCHEMBL4521400 | 0.86 | CETP (0.44) | MAPTHTTPOLBSMN1; SMN2 | |
| SCHEMBL4502243 | 0.85 | PRKAA2 (0.48) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1897872-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | PPARA, PPARG, PPARD | HTR1A 3048/4885TACR3 2435/4885TACR1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.